Incyte (INCY) Assets Average (2011 - 2026)
Incyte's (INCY) quarterly Assets Average came in at $7.6 billion in Q2 2026, up 31.47% YoY from $5.8 billion in Q2 2025, and up 6.4% on a QoQ basis from $7.1 billion in Q1 2026.
Incyte (INCY) Assets Average (2011 - 2026) Analysis & Trends
Incyte (INCY) has 16 years of Assets Average data on file, last reported at $7.6 billion in Q2 2026.
- Quarterly Assets Average rose 31.47% year-over-year to $7.6 billion in Q2 2026, while the trailing twelve-month figure through Jun 2026 was $7.6 billion (up 31.47% YoY) and the FY2025 annual result came in at $6.2 billion, up 1.44% from the prior year.
- Assets Average grew to $7.6 billion in Q2 2026, from $7.1 billion in the prior quarter.
- In the past five years, Assets Average ranged from a high of $7.6 billion in Q2 2026 to a low of $4.8 billion in Q3 2024.
- A 5-year average of $6.0 billion and a median of $5.9 billion in 2023 frame the typical range for Assets Average.
- Annual changes were most pronounced in 2022 — Assets Average surged 38.29% — and 2024, when it fell 23.2%.
- Tracing INCY's Assets Average over 5 years: stood at $5.7 billion in 2022, then grew by 16.03% to $6.6 billion in 2023, then declined by 20.6% to $5.2 billion in 2024, then grew by 27.08% to $6.6 billion in 2025, then increased by 14.47% to $7.6 billion in 2026.
- The last three Assets Average figures came in at $7.6 billion (Q2 2026), $7.1 billion (Q1 2026), and $6.6 billion (Q4 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Assets Avg. (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 26.95 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 41.30 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 3.29 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 8.86 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 16.08 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 19.82 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 5.34 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 2.09 Bn |
| 10 | Incyte | 24.15 Bn | 19.61 Bn | 1.57 Bn | 7.61 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 7.61 Bn |
| Mar 31, 2026 | 7.15 Bn |
| Dec 31, 2025 | 6.64 Bn |
| Sep 30, 2025 | 6.08 Bn |
| Jun 30, 2025 | 5.79 Bn |
| Mar 31, 2025 | 5.60 Bn |
| Dec 31, 2024 | 5.23 Bn |
| Sep 30, 2024 | 4.84 Bn |
| Jun 30, 2024 | 5.90 Bn |
| Mar 31, 2024 | 6.96 Bn |
| Dec 31, 2023 | 6.59 Bn |
| Sep 30, 2023 | 6.30 Bn |
| Jun 30, 2023 | 6.00 Bn |
| Mar 31, 2023 | 5.82 Bn |
| Dec 31, 2022 | 5.68 Bn |
| Sep 30, 2022 | 5.41 Bn |
| Jun 30, 2022 | 5.19 Bn |
| Mar 31, 2022 | 4.99 Bn |
| Dec 31, 2021 | 4.57 Bn |
| Sep 30, 2021 | 4.05 Bn |